Andrx Pharmaceuticals, Inc. v. Biovail Corp., No. 01-1050.
| Court | United States Supreme Court |
| Citation | 535 U.S. 931 |
| Docket Number | No. 01-1050. |
| Parties | ANDRX PHARMACEUTICALS, INC. <I>v.</I> BIOVAIL CORP. |
| Decision Date | 18 March 2002 |
v.
BIOVAIL CORP.
C. A. D. C. Cir. Certiorari denied. Reported below: 256 F. 3d 799.
To continue reading
Request your trial
6 practice notes
-
In re Ciprofloxacin Hydrochloride Antitrust Lit., No. 1:00-MDL-1383.
...safety and effectiveness. Andrx Pharms., Inc. v. Biovail Corp. Int'l, 256 F.3d 799, 801 (D.C.Cir. 2001) (citations omitted), cert. denied 535 U.S. 931, 122 S.Ct. 1305, 152 L.Ed.2d 216 (2002). Under the new guidelines, a generic drug manufacturer can file an Abbreviated New Drug Application ......
-
In re Tamoxifen Citrate Antitrust Lit., Docket No. 03-7641.
...in increasing the availability of generic drugs, it also wanted to protect the patent rights of the pioneer applicants."), cert. denied, 535 U.S. 931, 122 S.Ct. 1305, 152 L.Ed.2d 216 (2002); Schering-Plough Corp. v. F.T.C., 402 F.3d 1056, 1067 (11th Cir.2005) ("Although the exclusionary pow......
-
In re K–Dur Antitrust Litig., Nos. 10–2077
...considered a reverse payment in Andrx Pharmaceuticals, Inc. v. Biovail Corp. International, 256 F.3d 799 (D.C.Cir.2001), cert. denied,535 U.S. 931, 122 S.Ct. 1305, 152 L.Ed.2d 216 (2002). Unlike the instant case, that case did not involve a settlement resolving patent litigation. Rather, wh......
-
In re Tamoxifen Citrate Antitrust Litigation, Docket No. 03-7641.
...in increasing the availability of generic drugs, it also wanted to protect the patent rights of the pioneer applicants."), cert. denied, 535 U.S. 931, 122 S.Ct. 1305, 152 L.Ed.2d 216 (2002); Schering-Plough Corp. v. F.T.C., 402 F.3d 1056, 1067 (11th Cir.2005) ("Although the exclusionary pow......
Request a trial to view additional results
6 cases
-
In re Ciprofloxacin Hydrochloride Antitrust Lit., No. 1:00-MDL-1383.
...safety and effectiveness. Andrx Pharms., Inc. v. Biovail Corp. Int'l, 256 F.3d 799, 801 (D.C.Cir. 2001) (citations omitted), cert. denied 535 U.S. 931, 122 S.Ct. 1305, 152 L.Ed.2d 216 (2002). Under the new guidelines, a generic drug manufacturer can file an Abbreviated New Drug Application ......
-
In re Tamoxifen Citrate Antitrust Lit., Docket No. 03-7641.
...in increasing the availability of generic drugs, it also wanted to protect the patent rights of the pioneer applicants."), cert. denied, 535 U.S. 931, 122 S.Ct. 1305, 152 L.Ed.2d 216 (2002); Schering-Plough Corp. v. F.T.C., 402 F.3d 1056, 1067 (11th Cir.2005) ("Although the exclusionary pow......
-
In re K–Dur Antitrust Litig., Nos. 10–2077
...considered a reverse payment in Andrx Pharmaceuticals, Inc. v. Biovail Corp. International, 256 F.3d 799 (D.C.Cir.2001), cert. denied,535 U.S. 931, 122 S.Ct. 1305, 152 L.Ed.2d 216 (2002). Unlike the instant case, that case did not involve a settlement resolving patent litigation. Rather, wh......
-
In re Tamoxifen Citrate Antitrust Litigation, Docket No. 03-7641.
...in increasing the availability of generic drugs, it also wanted to protect the patent rights of the pioneer applicants."), cert. denied, 535 U.S. 931, 122 S.Ct. 1305, 152 L.Ed.2d 216 (2002); Schering-Plough Corp. v. F.T.C., 402 F.3d 1056, 1067 (11th Cir.2005) ("Although the exclusionary pow......
Request a trial to view additional results